TL;DR
Researchers have uncovered a novel feedback loop in hepatocellular carcinoma (HCC) involving DNMT1, miR-378a-3p, TRAF1, and the NF-κB pathway. This loop promotes angiogenesis, a key process in tumor growth and metastasis, suggesting that targeting this pathway could offer a new therapeutic strategy for HCC.
What Problem Does This Paper Address?
Hepatocellular carcinoma (HCC) is a highly vascularized tumor, meaning it relies heavily on new blood vessel formation (angiogenesis) for its growth and spread. While inhibiting angiogenesis has been a therapeutic goal, existing treatments have limitations. The precise molecular mechanisms driving angiogenesis in HCC, particularly the role of microRNAs (miRNAs) like miR-378a-3p, remain incompletely understood. This paper aims to elucidate the specific role of miR-378a-3p in HCC angiogenesis and identify the underlying molecular pathways.
Methods
The study employed a multi-pronged approach to investigate the role of miR-378a-3p in HCC:
- Expression Analysis: qRT-PCR and FISH assays were used to measure miR-378a-3p levels in HCC tissues and cell lines, and compared them to normal tissues. Publicly available datasets (TCGA, GEO) were also analyzed.
- Functional Assays (in vitro): Cell Counting Kit-8 (CCK-8) for cell viability, Transwell assays for migration and invasion, and tube formation assays on HUVECs were conducted to assess the impact of miR-378a-3p on angiogenesis.
- Functional Assays (in vivo): Matrigel plug assays and subcutaneous xenograft mouse models were used to evaluate the effect of miR-378a-3p on angiogenesis and tumor growth in a living system.
- Molecular Mechanism Studies:
- RNA sequencing (RNA-seq): To identify differentially expressed genes in response to miR-378a-3p manipulation.
- Bioinformatics Analysis: Tools like miRWalk, miRTarBase, STRING, and GEPIA were used to predict target genes, analyze pathway enrichment, and assess correlations between genes.
- Luciferase Reporter Assays: To confirm direct targeting of genes by miR-378a-3p and to investigate the regulatory role of p65 on the DNMT1 promoter.
- Western Blotting and Immunofluorescence: To assess protein expression levels and cellular localization of key signaling molecules (e.g., p65, phosphorylated IκBα, phosphorylated IKKβ, TRAF1, DNMT1, VEGF).
- Chromatin Immunoprecipitation (ChIP) Assays: To confirm direct binding of transcription factors (p65) to gene promoters.
- DNA Methylation Studies: Treatment with a demethylating agent (5-aza-CdR) and knockdown of DNA methyltransferases (DNMTs) were used to investigate the role of DNA methylation in miR-378a-3p silencing.
Datasets
- Human HCC Tissues: 108 pairs of primary HCC tissues and adjacent non-cancerous tissues were collected from patients undergoing surgery at Nantong University Affiliated Hospital. An additional cohort of 10 matched fresh HCC samples was also used.
- Publicly Available Datasets:
- The Cancer Genome Atlas (TCGA) database for analyzing differential miR-378a-3p expression, and correlations between miR-378a-3p, DNMT1, TRAF1, VEGFA, and p65.
- Gene Expression Omnibus (GEO) datasets (GSE54751, GSE108724, GSE174608) for assessing differential miR-378a-3p expression.
- Cell Lines:
- HCC cell lines: MHCC-97H, MHCC-97L, HCCLM3, LO2, SMMC-7721.
- Human umbilical vein endothelial cells (HUVECs).
Key Insights and Ideas
- miR-378a-3p as a Tumor Suppressor in HCC Angiogenesis: The study strongly suggests that miR-378a-3p acts as a brake on angiogenesis in HCC, with its downregulation correlating with increased tumor vascularity and poorer patient outcomes.
- TRAF1 as a Direct Target: miR-378a-3p directly targets TRAF1, a known activator of the NF-κB pathway. This targeting is crucial for miR-378a-3p's anti-angiogenic effects.
- NF-κB Pathway Activation: The downregulation of miR-378a-3p leads to increased TRAF1, which in turn activates the NF-κB signaling pathway, a key driver of angiogenesis.
- DNMT1-Mediated Silencing: DNA methylation is identified as a primary mechanism for miR-378a-3p silencing in HCC, with DNMT1 playing a critical role in this hypermethylation.
- A Positive Feedback Loop: A novel positive feedback loop is proposed: p65 (a component of NF-κB) upregulates DNMT1, which then hypermethylates and silences miR-378a-3p. This creates a self-reinforcing cycle that promotes angiogenesis.
Key Results
- Downregulation in HCC: miR-378a-3p expression was significantly lower in HCC tissues and cell lines compared to normal counterparts, and this downregulation was linked to higher microvessel density (MVD) and poorer patient survival.
- Inhibition of Angiogenesis: Overexpression of miR-378a-3p inhibited HUVEC proliferation, migration, invasion, and tube formation in vitro. In vivo, miR-378a-3p agomir treatment significantly reduced tumor growth and MVD.
- TRAF1 Targeting: Luciferase assays confirmed that miR-378a-3p directly targets TRAF1. Overexpression of miR-378a-3p reduced TRAF1 mRNA and protein levels, while its inhibition increased TRAF1.
- NF-κB Pathway Modulation: miR-378a-3p overexpression reduced NF-κB activation (indicated by decreased p65 nuclear translocation and reduced phosphorylation of IκBα and IKKβ), while its knockdown increased NF-κB activity.
- DNMT1's Role: Knockdown of DNMT1 increased miR-378a-3p expression, while DNMT1 overexpression suppressed it. DNMT1 expression was higher in HCC tissues and correlated negatively with miR-378a-3p levels.
- p65-DNMT1 Link: p65 was shown to bind to the DNMT1 promoter, activating its transcription and leading to increased DNMT1 expression.
Limitations and Future Work
- Therapeutic Target Potential: The authors propose the DNMT1/miR-378a-3p/TRAF1/NF-κB axis as a potential therapeutic target for HCC, but this study primarily focuses on elucidating the mechanism. Further research would be needed to develop and test specific therapeutic interventions targeting this pathway.
- In Vivo Validation of the Feedback Loop: While the study demonstrates the components of the feedback loop in vitro and in vivo, further in vivo experiments specifically designed to confirm the entire feedback loop's operation and its impact on tumor progression would strengthen the findings.
- Broader Clinical Significance: While correlations with MVD and survival are shown, further studies could explore the broader clinical implications and potential for using miR-378a-3p levels as a biomarker for prognosis or treatment response.
Summary updated